venetoclax,acalabrutinib,obinutuzumab
roche,astrazeneca,abbvie
['cll', 'venetoclax', 'acalabrutinib', 'inotuzumab']
acalabrutinib-venetoclax-obinotuzumab (avo) in high risk cll
- n=68, tp53/17p del
- median age 63 yr
- u-ighv 73%
- orr 100%, cr 43%
- umrd by mfc 86%, similar regardless of tp53
- aes &gt;&gt; g3/4 sepsis 5.8% . af (3%, g 1 and 3) #ash22 
Guidelines, updates, Questions, Meetings in Hematology.